Integra LifeSciences (NASDAQ:IART) Issues FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 3.010-3.110 for the period, compared to the consensus earnings per share estimate of 3.190. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its FY24 guidance to $3.01-3.11 EPS.

Analyst Ratings Changes

A number of research firms have commented on IART. Wells Fargo & Company lowered shares of Integra LifeSciences from an overweight rating to an equal weight rating and decreased their target price for the stock from $45.00 to $25.00 in a research report on Tuesday. Truist Financial decreased their price objective on shares of Integra LifeSciences from $37.00 to $25.00 and set a hold rating on the stock in a research report on Tuesday. StockNews.com downgraded Integra LifeSciences from a buy rating to a hold rating in a research report on Tuesday, April 30th. Oppenheimer lowered Integra LifeSciences from an outperform rating to a market perform rating in a research note on Tuesday. Finally, JMP Securities dropped their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating for the company in a research report on Thursday, February 29th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $39.00.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded up $1.36 during trading hours on Tuesday, hitting $24.50. 1,020,126 shares of the company’s stock traded hands, compared to its average volume of 772,755. Integra LifeSciences has a 52 week low of $22.36 and a 52 week high of $51.12. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 28.17, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company’s fifty day simple moving average is $33.33 and its two-hundred day simple moving average is $38.33. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The company had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 earnings per share. As a group, equities analysts anticipate that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.